Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karlien Mul

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Neuromuscular Disorders : NMD|August 31, 2024
Comprehensive four-year disease progression assessment of myotonic dystrophy type 1Leandre A la Fontaine, Johanna E Bruijnes, Fran Hp Smulders, et al.
BMC Neurology|August 18, 2016
Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD)Rianne J M Goselink, Tim H A Schreuder, Karlien Mul, et al.
European Journal of Human Genetics : EJHG|November 23, 2017
Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2Richard Jlf Lemmers, Patrick J van der Vliet, Judit Balog, et al.
Neuromuscular Disorders : NMD|February 20, 2025
Strength and functional correlates of reachable workspace in facioscapulohumeral muscular dystrophyLeo H Wang, Maya N Hatch, Michael P McDermott, et al.
Neuromuscular Disorders : NMD|July 3, 2023
Lean tissue mass measurements by dual-energy X-ray absorptiometry and associations with strength and functional outcome measures in facioscapulohumeral muscular dystrophyLeo H Wang, Doris G Leung, Kathryn R Wagner, et al.
Neuromuscular Disorders : NMD|March 20, 2026
Late-onset facioscapulohumeral muscular dystrophy defines a distinct clinical subgroupGiulia Tammam, Sandra Dhifallah, Hongmei Yang, et al.
Plos One|December 11, 2025
Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history studyKarlien Mul, Kate Eichinger, Man Hung, et al.
Neurology|July 8, 2018
FSHD type 2 and Bosma arhinia microphthalmia syndrome: Two faces of the same mutationKarlien Mul, Richard J L F Lemmers, Marjolein Kriek, et al.
Neurology|February 26, 2026
Prospective Study of Video Hand Opening Time as a Quantitative Measurement of Myotonia in Patients With Myotonic Dystrophy Type 1Kristofoor E Leeuwenberg, Valeria A Sansone, Johanna Hamel, et al.
Muscle & Nerve|May 11, 2026
Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1Valeria A Sansone, Andrea Lizio, Carola R Ferrari Aggradi, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Neuromuscular Disorders : NMD|August 31, 2024
Comprehensive four-year disease progression assessment of myotonic dystrophy type 1Leandre A la Fontaine, Johanna E Bruijnes, Fran Hp Smulders, et al.
BMC Neurology|August 18, 2016
Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD)Rianne J M Goselink, Tim H A Schreuder, Karlien Mul, et al.
European Journal of Human Genetics : EJHG|November 23, 2017
Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2Richard Jlf Lemmers, Patrick J van der Vliet, Judit Balog, et al.
Neuromuscular Disorders : NMD|February 20, 2025
Strength and functional correlates of reachable workspace in facioscapulohumeral muscular dystrophyLeo H Wang, Maya N Hatch, Michael P McDermott, et al.
Neuromuscular Disorders : NMD|July 3, 2023
Lean tissue mass measurements by dual-energy X-ray absorptiometry and associations with strength and functional outcome measures in facioscapulohumeral muscular dystrophyLeo H Wang, Doris G Leung, Kathryn R Wagner, et al.
Neuromuscular Disorders : NMD|March 20, 2026
Late-onset facioscapulohumeral muscular dystrophy defines a distinct clinical subgroupGiulia Tammam, Sandra Dhifallah, Hongmei Yang, et al.
Plos One|December 11, 2025
Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history studyKarlien Mul, Kate Eichinger, Man Hung, et al.
Neurology|July 8, 2018
FSHD type 2 and Bosma arhinia microphthalmia syndrome: Two faces of the same mutationKarlien Mul, Richard J L F Lemmers, Marjolein Kriek, et al.
Neurology|February 26, 2026
Prospective Study of Video Hand Opening Time as a Quantitative Measurement of Myotonia in Patients With Myotonic Dystrophy Type 1Kristofoor E Leeuwenberg, Valeria A Sansone, Johanna Hamel, et al.
Muscle & Nerve|May 11, 2026
Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1Valeria A Sansone, Andrea Lizio, Carola R Ferrari Aggradi, et al.
Pageof 6